molibresib

Small moleculeexperimental

Chemistry & pharmacology

Loading structure…

SMILES

CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc21
Mol. weight
423.9 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • gsk525762
  • gsk525762
  • gsk525762
  • gsk 525762
  • gsk525762a
  • gsk 525762a
  • gsk-525762a
  • i-bet762
  • i-bet compound
  • ibet compound

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT04116359Phase 1/Phase 2 (Phase 2)Dec 6, 2019Harvard University, National Cancer Institute (NCI)
NCT03925428Phase 1Sep 1, 2019National Cancer Institute (NCI), Yale University
NCT03266159Phase 2Nov 27, 2017GlaxoSmithKline
NCT03150056Phase 1Jun 12, 2017GlaxoSmithKline
NCT02964507Phase 2Feb 2, 2017GlaxoSmithKline
NCT02706535Phase 1May 1, 2016GlaxoSmithKline
NCT01943851Phase 1May 14, 2014GlaxoSmithKline
NCT01587703Phase 1Mar 28, 2012GlaxoSmithKline
NCT03702036N/AGlaxoSmithKline
Showing 9 of 9 trials
Page 1 / 1

Organizations

Research & Development (4)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
GlaxoSmithKlineFor profit7732012
National Cancer Institute (NCI)Government2222019
Harvard UniversityAcademic/Hospital1012019
Yale UniversityAcademic/Hospital1012019
4 organizations
Page 1 / 1